Multiomic Mass Spectrometry Imaging to Advance Future Pathological Understanding of Ocular Disease
Joshua Millar,
Ema Ozaki,
Susan Campbell,
Catherine Duckett,
Sarah Doyle,
Laura M. Cole
Affiliations
Joshua Millar
Centre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK
Ema Ozaki
Immunobiology Research Group, Department of Clinical Medicine, Trinity College Institute of Neuroscience (TCIN), School of Medicine, Trinity College Dublin (TCD), D02 R590 Dublin 2, Ireland
Susan Campbell
Centre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK
Catherine Duckett
Centre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK
Sarah Doyle
Immunobiology Research Group, Department of Clinical Medicine, Trinity College Institute of Neuroscience (TCIN), School of Medicine, Trinity College Dublin (TCD), D02 R590 Dublin 2, Ireland
Laura M. Cole
Centre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK
Determining the locations of proteins within the eye thought to be involved in ocular pathogenesis is important to determine how best to target them for therapeutic benefits. However, immunohistochemistry is limited by the availability and specificity of antibodies. Additionally, the perceived role of both essential and non-essential metals within ocular tissue has been at the forefront of age-related macular degeneration (AMD) pathology for decades, yet even key metals such as copper and zinc have yet to have their roles deconvoluted. Here, mass spectrometry imaging (MSI) is employed to identify and spatially characterize both proteomic and metallomic species within ocular tissue to advance the application of a multiomic imaging methodology for the investigation of ocular diseases.
